Velarion Records
Free. Unsubscribe any time.

BridgeBio Pharma, Inc. (BBIO)

BridgeBio Pharma, Inc. filed 56 Form 4 statements naming a Rule 10b5-1 trading plan in the 2025 filing year, by 10 reporting owners, covering 210 transactions and 3,353,627 shares. 20 carry the SEC's AFF10B5ONE flag; 36 name a plan only in a footnote. 9 results prints are on file in the same window.

What stands out

Trades in BridgeBio Pharma, Inc. 210

Adoption dates in BridgeBio Pharma, Inc. 12

Results prints in BridgeBio Pharma, Inc. 9

Trades before a print in BridgeBio Pharma, Inc. 33

Interval to BridgeBio Pharma, Inc.’s next reported results date

How the interval and sources are counted →

Adoption dates BridgeBio Pharma, Inc. states

Filing text: “10b5-1 sales plan adopted by the Reporting Person on March 22, 2024”

Reported results dates on file

A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.

Other companies with plan records

Sources: SEC EDGAR full-text search and the SEC submissions API.